Work

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Year: 2023

Type: other

Abstract: Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.

DOI: 10.1158/1078-0432.22553356

Authors: Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362540897

Cites:

Cited by:

Related to: 7